Shareholders Approve SL Bio Business Combination and Extend Deadline to February 2027
HSPT sits 26% above its 52-week low of $9.51.
Summary
Shareholders of Horizon Space Acquisition II Corp. approved the business combination with SL Bio and extended the deadline to complete the merger until February 2027, providing a clear path forward for the SPAC.
Key Events · M&A and Partnerships · HSPT
-
Business Combination Approved
Shareholders approved the Business Combination Agreement with SL Science Holding Limited (PubCo) and SL BIO Ltd., moving the company closer to completing its merger.
-
Deadline Extended to February 2027
Shareholders approved amendments to the Articles of Association and the Investment Management Trust Agreement, extending the deadline to complete a business combination from February 18, 2026, to February 18, 2027.
-
New Director Appointed
William Wang Ching-Dong was approved as the sole director of HSPT, effective upon the First Merger Effective Time.
Analysis · HSPT · Real Estate & Construction
Horizon Space Acquisition II Corp. shareholders have approved the proposed business combination with SL Bio, a critical step for the SPAC to complete its de-SPAC transaction. Concurrently, shareholders also approved an extension of the deadline to complete a business combination until February 18, 2027. This dual approval provides the company with both the mandate to proceed with the merger and additional time to finalize the transaction, mitigating immediate liquidation risk. The appointment of a new sole director effective upon merger completion further signals progress towards the combined entity.
At the time of this filing, HSPT was trading at $12.00 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $109M. The 52-week trading range was $9.51 to $14.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.